Belimumab and voclosporin for lupus nephritis: final policy recommendations

Belimumab and voclosporin for lupus nephritis: final policy recommendations

Collection:
Health Policy and Services Research
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, April 16, 2021
Language(s):
English
Format:
Text
Subject(s):
Calcineurin Inhibitors
Immunosuppressive Agents
Lupus Nephritis -- drug therapy
United States
Genre(s):
Technical Report
Abstract:
The following policy recommendations reflect the main themes and points made during the Policy Roundtable discussion at the March 26, 2021 New England CEPAC public meeting on the use of belimumab and voclosporin for the treatment of lupus nephritis. At the meeting, ICER presented the findings of its revised report on these treatments and the New England CEPAC voting council deliberated on key questions related to their comparative clinical effectiveness, potential other benefits and contextual considerations, and long-term value for money at current prices. Following the votes, ICER convened a Policy Roundtable of two patients, two clinical experts, two payers, one patient advocate, and two representatives from pharmaceutical manufacturers to discuss how best to apply the evidence and votes to real-world practice and policy. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (10 pages))
NLM Unique ID:
9918401788206676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918401788206676